Showing 5341-5350 of 10176 results for "".
- Report: Antibiotics Linked to Shorter Biologic Persistence in Psoriasishttps://practicaldermatology.com/news/report-antibiotics-linked-to-shorter-biologic-persistence-in-psoriasis/2484451/Antibiotic exposure is associated with reduced persistence of biologic therapies in patients with psoriasis, according to findings from a nationwide French cohort study published in JAMA Dermatology.
- Remibrutinib Outperforms Placebo in Chronic Spontaneous Urticaria Control: Studyhttps://practicaldermatology.com/news/remibrutinib-outperforms-placebo-in-chronic-spontaneous-urticaria-control-study/2484429/Remibrutinib showed rapid and sustained efficacy in adults with chronic spontaneous urticaria (CSU) in a pooled analysis of the phase 3 REMIX-1 and REMIX-2 studies. The multicenter, double-blind, placebo-controlled trials looke
- Large Study Shows No Link Found Between Pemphigus and Psychiatric Disordershttps://practicaldermatology.com/news/large-study-shows-no-link-found-between-pemphigus-and-psychiatric-disorders/2484421/Results from a large retrospective cohort study analyzing more than 120 million U.S. electronic health records found no increased risk of psychiatric disorders in patients with pemphigus. "While 10–15% of dermatology patients ar
- Seborrheic Dermatitis Linked to Systemic Epithelial Barrier Diseases: Analysishttps://practicaldermatology.com/news/seborrheic-dermatitis-linked-to-systemic-epithelial-barrier-diseases-analysis/2484390/Findings from a new retrospective cohort suggest individuals living with seborrheic dermatitis are more likely to have other epithelial barrier diseases such as rosacea, alopecia areata, and celiac disease. Investigators publish
- From ACAAI: Tapinarof Cream Shows Early Efficacy in Pediatric AD Regardless of Comorbiditieshttps://practicaldermatology.com/news/from-acaai-tapinarof-cream-shows-early-efficacy-in-pediatric-ad-regardless-of-comorbidities/2484383/New data from a pooled sub-analysis of the ADORING 1 and 2 trials show that VTAMA® (tapinarof) cream, 1%, was associated with improvements in children aged 2 to 17 with moderate to severe atopic dermatitis (AD). Results from th
- FDA Clears Ultherapy PRIME for Skin Laxity on Arms, Abdomenhttps://practicaldermatology.com/news/fda-clears-ultherapy-prime-for-skin-laxity-on-arms-abdomen/2484325/The US Food and Drug Administration (FDA) has cleared Ultherapy PRIME for the treatment of skin laxity on the anterior arms, posterior arms, and abdomen, according to Merz Aesthetics. The device is now FDA-cleared for noninvasive lifting and firming of the face, neck, décolleté, and body.
- Analysis: Fibrotic Skin Diseases Linked to Elevated ASCVD Riskhttps://practicaldermatology.com/news/analysis-fibrotic-skin-diseases-linked-to-elevated-ascvd-risk/2484276/Patients with fibrotic skin diseases may have an elevated risk of atherosclerotic cardiovascular disease (ASCVD), according to new real-world data from the TriNetX platform. The study researchers conducted a retrospective cohort
- Pediatric AD: Tapinarof Cream 1% Delivers Clear Skin and Reduced Burdenhttps://practicaldermatology.com/news/pediatric-ad-tapinarof-cream-1-delivers-clear-skin-and-reduced-burden/2484254/In the pivotal ADORING 1 and 2 phase 3 trials, tapinarof cream 1% (VTAMA, Organon) showed consistent and statistically significant efficacy across all pediatric age groups in children with atopic dermatitis (AD), with benefits extending to sleep and family impact o
- BE HEARD: Bimekizumab Shows Sustained Relief in HS Symptoms Through 3 Yearshttps://practicaldermatology.com/news/be-heard-bimekizumab-shows-sustained-relief-in-hs-symptoms-through-3-years/2484274/Long-term data from the BE HEARD study showed BIMZELX® (bimekizumab-bkzx) was linked with sustained reductions in draining tunnels and clinically meaningful skin pain relief in patients with moderate-to-severe hidradenitis suppurativa (HS) through three years. <
- Tapinarof Sustains AD Remission for 75+ Days Post-Treatmenthttps://practicaldermatology.com/news/tapinarof-sustains-ad-remission-for-75-days-post-treatment/2484253/New long-term data from the ADORING 3 trial show that tapinarof cream 1% (VTAMA, Organon), a non-steroidal topical aryl hydrocarbon receptor agonist, can sustain low disease activity and pruritus in patients with atopic dermatitis (AD), including children as young